February 24, 2023

Updated Results From the ADAURA Trial: Continued Disease-Free Survival Benefit With Adjuvant Osimertinib vs Placebo in EGFR-Mutated Stage IB–IIIA NSCLC

As reported in the Journal of Clinical Oncology by Roy S. Herbst, MD, PhD, of Yale Cancer Center and Yale School of Medicine, and colleagues, updated findings in the phase III ADAURA trial showed cont...

The ASCO Post

January 31, 2024

Accelerated Hypofractionated Chemoradiation With Adaptive SABR Boost in Locally Advanced, Unresectable NSCLC

According to a U.S. single-center radiation dose-expansion study, chemoradiation with adaptively increased stereotactic ablative radiotherapy (SABR) boost doses was safe and effective in patients with...

The ASCO Post

August 08, 2024

EGFR- and ALK-Altered NSCLC: TKIs With Stereotactic Radiosurgery for Brain Metastases

The addition of upfront stereotactic radiosurgery to CNS-penetrant TKI treatment prolonged time to CNS progression vs TKI treatment alone in TKI-naive patients with brain metastases from EGFR- and ALK...

The ASCO Post

April 09, 2024

RP1 Immunotherapy in Solid Organ Transplant Recipients With Skin Cancer

Researchers evaluated a novel oncolytic immunotherapy in solid organ transplant recipients with skin cancer. They presented their findings at the AACR Annual Meeting 2024.

The ASCO Post

November 27, 2023

Iruplinalkib Demonstrates Improved Efficacy and Tolerance vs Crizotinib in ALK Inhibitor–Naive, Advanced ALK-Positive NSCLC

The novel ALK tyrosine kinase inhibitor iruplinalkib has demonstrated potential for a difficult-to-treat subset of patients with non–small cell lung cancer (NSCLC), according to data presented at the...

The ASCO Post

October 09, 2024

Stereotactic vs Hypofractionated Radiotherapy for Inoperable Stage I NSCLC

The Canadian phase III LUSTRE trial, reported in JAMA Oncology by Swaminath et al, evaluated local tumor control for stereotactic body radiotherapy vs hypofractionated conventional radiotherapy in pat...

The ASCO Post

August 10, 2023

First-Line Atezolizumab vs Single-Agent Chemotherapy in Patients With Advanced NSCLC Ineligible for Platinum-Based Chemotherapy

In the phase III IPSOS trial reported in The Lancet, Lee et al found that first-line atezolizumab improved overall survival vs single-agent chemotherapy in patients with advanced non–small cell lung c...

The ASCO Post

January 11, 2023

FoundationOne Liquid CDx Receives FDA Approval as a Companion Diagnostic for Entrectinib

On January 4, the U.S. Food and Drug Administration (FDA) approved FoundationOne Liquid CDx to be used as a companion diagnostic to identify patients with ROS1-positive non–small cell lung cancer or N...

The ASCO Post

August 26, 2024

LIBRETTO-431 Trial Shows Selpercatinib Is Effective in East Asian Patients With RET Fusion–Positive Non–Small Cell Lung Cancer

A subgroup analysis of data from the LIBRETTO-431 trial showed that the selective RET inhibitor selpercatinib safely improved progression-free survival compared to chemotherapy plus pembrolizumab in E...

The ASCO Post